Highlights in Metastatic Prostate Cancer From the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium

Volume 14, Issue 4, Supplement 5  April 2016

A SPECIAL MEETING REVIEW EDITION

Highlights in Metastatic Prostate Cancer From the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium

A Review of Selected Presentations From the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium

January 7-9, 2016 • San Francisco, California

Special Reporting on: 

• Interim Results From ERADICATE: An Open-Label Phase 2 Study of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Castration-Resistant Prostate Cancer Subjects With Symptomatic Bone Metastases

• Challenging Cases Panel Discussion

• Radium-223 (Ra-223) Re-Treatment (Re-tx): First Experience From an International, Multicenter, Prospective Study in Patients (Pts) With Castration-Resistant Prostate Cancer and Bone Metastases (mCRPC)

• Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Survival Results From STAMPEDE (NCT00268476)

• Differential Side Effects Profile in mCRPC Patients Treated With Abiraterone or Enzalutamide: A Meta-Analysis of Randomized Controlled Trials

• Phase II Clinical Study of Radium-223 Chloride (BAY 88-8223) in Japanese Patients With Symptomatic Castration-Resistant Prostate Cancer (CRPC) With Bone Metastases

PLUS  Meeting Abstract Summaries

With Expert Commentary by:

Neal D. Shore, MD, FACS
Medical Director, CPI
Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina